Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. His research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab (Rituxan®) for the treatment of patients’ lymphomas. Dr. Levy is currently conducting clinical trials of in situ therapeutic vaccination.
Dr. Levy is a member of the National Academy of Medicine National Academy of Sciences.